APO Research
Talk to an analyst

APO RESEARCH · REPORT

HIV Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global HIV Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025181 pages

Choose your research edition.

Industry ResearchHIV Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV Drugs Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal HIV Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global HIV Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for HIV Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for HIV Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HIV Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for HIV Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of HIV Drugs include Johnson & Johnson, Merck, GlaxoSmithKline, Gilead Sciences and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global HIV Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of HIV Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents HIV Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the HIV Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

HIV Drugs Segment by Company

Johnson & Johnson

Merck

GlaxoSmithKline

Gilead Sciences

Bristol-Myers Squibb

HIV Drugs Segment by Type

Fusion Inhibitors

Entry Inhibitors - CCR5 Co-Receptor Antagonist

Nucleoside Reverse Transcriptase Inhibitors

Non-Nucleoside Reverse Transcriptase Inhibitors

Multi-Class Combination Products

Protease Inhibitors

HIV Integrase Strand Transfer Inhibitors

HIV Drugs Segment by Application

Online Pharmacies

Hospital Pharmacies

Retail Pharmacies

Others

HIV Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the HIV Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of HIV Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of HIV Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of HIV Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. HIV Drugs Industry Trends Table 2. HIV Drugs Industry Drivers Table 3. HIV Drugs Industry Opportunities and Challenges Table 4. HIV Drugs Industry Restraints Table 5. Global HIV Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global HIV Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global HIV Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global HIV Drugs Sales Market Share by Manufacturers Table 9. Global HIV Drugs Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global HIV Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global HIV Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global HIV Drugs Manufacturers, Product Type & Application Table 13. Global HIV Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global HIV Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Fusion Inhibitors Table 17. Major Manufacturers of Entry Inhibitors - CCR5 Co-Receptor Antagonist Table 18. Major Manufacturers of Nucleoside Reverse Transcriptase Inhibitors Table 19. Major Manufacturers of Non-Nucleoside Reverse Transcriptase Inhibitors Table 20. Major Manufacturers of Multi-Class Combination Products Table 21. Major Manufacturers of Protease Inhibitors Table 22. Major Manufacturers of HIV Integrase Strand Transfer Inhibitors Table 23. Global HIV Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global HIV Drugs Sales by Type (2021-2026) & (k units) Table 25. Global HIV Drugs Sales by Type (2027-2032) & (k units) Table 26. Global HIV Drugs Sales Market Share by Type (2021-2026) Table 27. Global HIV Drugs Sales Market Share by Type (2027-2032) Table 28. Global HIV Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 29. Global HIV Drugs Revenue by Type (2021-2026) & (k units) Table 30. Global HIV Drugs Revenue by Type (2027-2032) & (k units) Table 31. Global HIV Drugs Revenue Market Share by Type (2021-2026) Table 32. Global HIV Drugs Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Online Pharmacies Table 34. Major Manufacturers of Hospital Pharmacies Table 35. Major Manufacturers of Retail Pharmacies Table 36. Major Manufacturers of Others Table 37. Global HIV Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global HIV Drugs Sales by Application (2021-2026) & (k units) Table 39. Global HIV Drugs Sales by Application (2027-2032) & (k units) Table 40. Global HIV Drugs Sales Market Share by Application (2021-2026) Table 41. Global HIV Drugs Sales Market Share by Application (2027-2032) Table 42. Global HIV Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 43. Global HIV Drugs Revenue by Application (2021-2026) & (k units) Table 44. Global HIV Drugs Revenue by Application (2027-2032) & (k units) Table 45. Global HIV Drugs Revenue Market Share by Application (2021-2026) Table 46. Global HIV Drugs Revenue Market Share by Application (2027-2032) Table 47. Global HIV Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 48. Global HIV Drugs Sales by Region (2021-2026) & (k units) Table 49. Global HIV Drugs Sales Market Share by Region (2021-2026) Table 50. Global HIV Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 51. Global HIV Drugs Sales Forecasted Market Share by Region (2027-2032) Table 52. North America HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. North America HIV Drugs Sales by Country (2021-2026) & (k units) Table 54. North America HIV Drugs Sales by Country (2027-2032) & (k units) Table 55. Europe HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Europe HIV Drugs Sales by Country (2021-2026) & (k units) Table 57. Europe HIV Drugs Sales by Country (2027-2032) & (k units) Table 58. Asia Pacific HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. Asia Pacific HIV Drugs Sales by Country (2021-2026) & (k units) Table 60. Asia Pacific HIV Drugs Sales by Country (2027-2032) & (k units) Table 61. South America, Middle East and Africa HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 62. South America, Middle East and Africa HIV Drugs Sales by Country (2021-2026) & (k units) Table 63. South America, Middle East and Africa HIV Drugs Sales by Country (2027-2032) & (k units) Table 64. Global HIV Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global HIV Drugs Revenue by Region (2021-2026) & (US$ Million) Table 66. Global HIV Drugs Revenue by Region (2027-2032) & (US$ Million) Table 67. Global HIV Drugs Revenue Market Share by Region (2021-2026) Table 68. Global HIV Drugs Revenue Market Share by Region (2027-2032) Table 69. Johnson & Johnson Company Information Table 70. Johnson & Johnson Business Overview Table 71. Johnson & Johnson HIV Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Johnson & Johnson HIV Drugs Product Portfolio Table 73. Johnson & Johnson Recent Development Table 74. Merck Company Information Table 75. Merck Business Overview Table 76. Merck HIV Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Merck HIV Drugs Product Portfolio Table 78. Merck Recent Development Table 79. GlaxoSmithKline Company Information Table 80. GlaxoSmithKline Business Overview Table 81. GlaxoSmithKline HIV Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. GlaxoSmithKline HIV Drugs Product Portfolio Table 83. GlaxoSmithKline Recent Development Table 84. Gilead Sciences Company Information Table 85. Gilead Sciences Business Overview Table 86. Gilead Sciences HIV Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Gilead Sciences HIV Drugs Product Portfolio Table 88. Gilead Sciences Recent Development Table 89. Bristol-Myers Squibb Company Information Table 90. Bristol-Myers Squibb Business Overview Table 91. Bristol-Myers Squibb HIV Drugs Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Bristol-Myers Squibb HIV Drugs Product Portfolio Table 93. Bristol-Myers Squibb Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. HIV Drugs Distributors List Table 97. HIV Drugs Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. HIV Drugs Product Image Figure 2. Global HIV Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global HIV Drugs Sales (2021-2032) & (k units) Figure 5. Global HIV Drugs Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 HIV Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Fusion Inhibitors Image Figure 9. Entry Inhibitors - CCR5 Co-Receptor Antagonist Image Figure 10. Nucleoside Reverse Transcriptase Inhibitors Image Figure 11. Non-Nucleoside Reverse Transcriptase Inhibitors Image Figure 12. Multi-Class Combination Products Image Figure 13. Protease Inhibitors Image Figure 14. HIV Integrase Strand Transfer Inhibitors Image Figure 15. Global HIV Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global HIV Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global HIV Drugs Sales Market Share by Type (2021-2032) Figure 18. Global HIV Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 19. Global HIV Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global HIV Drugs Revenue Market Share by Type (2021-2032) Figure 21. Online Pharmacies Image Figure 22. Hospital Pharmacies Image Figure 23. Retail Pharmacies Image Figure 24. Others Image Figure 25. Global HIV Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global HIV Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global HIV Drugs Sales Market Share by Application (2021-2032) Figure 28. Global HIV Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 29. Global HIV Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global HIV Drugs Revenue Market Share by Application (2021-2032) Figure 31. North America HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 32. North America HIV Drugs Sales Market Share by Country (2021-2032) Figure 33. U.S. HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 34. Canada HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. Mexico HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. Europe HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. Europe HIV Drugs Sales Market Share by Country (2021-2032) Figure 38. Germany HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 39. France HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 40. U.K. HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. Italy HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. Netherlands HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. Asia Pacific HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. Asia Pacific HIV Drugs Sales Market Share by Country (2021-2032) Figure 45. China HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. Japan HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 47. South Korea HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 48. Southeast Asia HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. India HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. Australia HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. South America, Middle East and Africa HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. South America, Middle East and Africa HIV Drugs Sales Market Share by Country (2021-2032) Figure 53. Brazil HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. South Africa HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. Saudi Arabia HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 56. Turkey HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 57. Argentina HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 58. UAE HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 59. Egypt HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 60. Chile HIV Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 61. Global HIV Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global HIV Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America HIV Drugs Revenue (2021-2032) & (US$ Million) Figure 64. North America HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe HIV Drugs Revenue (2021-2032) & (US$ Million) Figure 66. Europe HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific HIV Drugs Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa HIV Drugs Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. HIV Drugs Value Chain Figure 72. Manufacturing Cost Structure Figure 73. HIV Drugs Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Fusion Inhibitors
  • Entry Inhibitors - CCR5 Co-Receptor Antagonist
  • Nucleoside Reverse Transcriptase Inhibitors
  • Non-Nucleoside Reverse Transcriptase Inhibitors
  • Multi-Class Combination Products
  • Protease Inhibitors
  • HIV Integrase Strand Transfer Inhibitors
Applications
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
Companies covered
  • Johnson & Johnson
  • Merck
  • GlaxoSmithKline
  • Gilead Sciences
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global HIV Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global HIV Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global HIV Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global HIV Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global HIV Drugs Market Dynamics
  1. 2.1 HIV Drugs Industry Trends
  2. 2.2 HIV Drugs Industry Drivers
  3. 2.3 HIV Drugs Industry Opportunities and Challenges
  4. 2.4 HIV Drugs Industry Restraints
3 HIV Drugs Market by Manufacturers
  1. 3.1 Global HIV Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global HIV Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global HIV Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global HIV Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global HIV Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global HIV Drugs Manufacturers, Product Type & Application
  7. 3.7 Global HIV Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global HIV Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 HIV Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 HIV Drugs Tier 1, Tier 2, and Tier 3
4 HIV Drugs Market by Type
  1. 4.1 HIV Drugs Type Introduction
  2. 4.1.1 Fusion Inhibitors
  3. 4.1.2 Entry Inhibitors - CCR5 Co-Receptor Antagonist
  4. 4.1.3 Nucleoside Reverse Transcriptase Inhibitors
  5. 4.1.4 Non-Nucleoside Reverse Transcriptase Inhibitors
  6. 4.1.5 Multi-Class Combination Products
  7. 4.1.6 Protease Inhibitors
  8. 4.1.7 HIV Integrase Strand Transfer Inhibitors
  9. 4.2 Global HIV Drugs Sales by Type
  10. 4.2.1 Global HIV Drugs Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global HIV Drugs Sales by Type (2021-2032)
  12. 4.2.3 Global HIV Drugs Sales Market Share by Type (2021-2032)
  13. 4.3 Global HIV Drugs Revenue by Type
  14. 4.3.1 Global HIV Drugs Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global HIV Drugs Revenue by Type (2021-2032)
  16. 4.3.3 Global HIV Drugs Revenue Market Share by Type (2021-2032)
5 HIV Drugs Market by Application
  1. 5.1 HIV Drugs Application Introduction
  2. 5.1.1 Online Pharmacies
  3. 5.1.2 Hospital Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.1.4 Others
  6. 5.2 Global HIV Drugs Sales by Application
  7. 5.2.1 Global HIV Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global HIV Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global HIV Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global HIV Drugs Revenue by Application
  11. 5.3.1 Global HIV Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global HIV Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global HIV Drugs Revenue Market Share by Application (2021-2032)
6 Global HIV Drugs Sales by Region
  1. 6.1 Global HIV Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global HIV Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global HIV Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global HIV Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America HIV Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe HIV Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific HIV Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa HIV Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa HIV Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global HIV Drugs Revenue by Region
  1. 7.1 Global HIV Drugs Revenue by Region
  2. 7.1.1 Global HIV Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global HIV Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global HIV Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global HIV Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America HIV Drugs Revenue (2021-2032)
  8. 7.2.2 North America HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe HIV Drugs Revenue (2021-2032)
  11. 7.3.2 Europe HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific HIV Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa HIV Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa HIV Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson HIV Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson HIV Drugs Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck HIV Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck HIV Drugs Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 GlaxoSmithKline
  14. 8.3.1 GlaxoSmithKline Company Information
  15. 8.3.2 GlaxoSmithKline Business Overview
  16. 8.3.3 GlaxoSmithKline HIV Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline HIV Drugs Product Portfolio
  18. 8.3.5 GlaxoSmithKline Recent Developments
  19. 8.4 Gilead Sciences
  20. 8.4.1 Gilead Sciences Company Information
  21. 8.4.2 Gilead Sciences Business Overview
  22. 8.4.3 Gilead Sciences HIV Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Sciences HIV Drugs Product Portfolio
  24. 8.4.5 Gilead Sciences Recent Developments
  25. 8.5 Bristol-Myers Squibb
  26. 8.5.1 Bristol-Myers Squibb Company Information
  27. 8.5.2 Bristol-Myers Squibb Business Overview
  28. 8.5.3 Bristol-Myers Squibb HIV Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bristol-Myers Squibb HIV Drugs Product Portfolio
  30. 8.5.5 Bristol-Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 HIV Drugs Value Chain Analysis
  2. 9.1.1 HIV Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 HIV Drugs Production Mode & Process
  6. 9.2 HIV Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 HIV Drugs Distributors
  9. 9.2.3 HIV Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst